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Abstract 
Background: In France, data regarding epidemiology and management of severe asthma are scarce. The objective 
of this study was to describe asthma phenotypes using a cluster analysis in severe asthmatics recruited in a real world 
setting.
Methods: The study design was prospective, observational and multicentric. The patients included were adults with 
severe asthma (GINA 4–5) followed‑up in French Non Academic Hospital between May 2016 and June 2017. One 
hundred and seven physicians included 1502 patients. Both sociodemographic and clinical variables were collected. 
Hierarchical cluster analysis was performed by the Ward method followed by k‑means cluster analysis on a population 
of 1424 patients.
Results: Five clusters were identified: cluster 1 (n = 690, 47%) called early onset allergic asthma (47.5% with asthma 
before 12 years), cluster 2 (n = 153, 10.5%): obese asthma (63.5% with BMI > 30 kg/m2), cluster 3 (n = 299, 20.4%): late‑
onset asthma with severe obstructive syndrome (89% without atopy), cluster 4 (n = 143, 9.8%): eosinophilic asthma 
(51.7% had more than 500 eosinophils/mm3), and cluster 5 (n = 139, 9.5%): aspirin sensitivity asthma (63% had severe 
asthma attacks).
Conclusions: In our population of adults with severe asthma followed by pulmonologists, five distinct phenotypes 
were identified and are quite different from those mentioned in previous studies.
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Introduction
Asthma is a heterogeneous disease that presents with a 
variety of symptoms and variable response to medication.
Management of mild to moderate asthma is based on 
the same treatment for each patient, variable according to 
asthma control and exacerbations risk [1] (GINA 2018). 
By contrast, as patients with difficult-to-treat asthma or 
severe asthma had a high rate of exacerbations and poor 
asthma control and poor quality of life despite manage-
ment, improvement in therapeutic management had 
leaded to better understanding in asthma phenotypes.
A decade ago, asthma phenotypes were defined by two 
criteria i.e. atopic status and age onset of asthma (child-
hood versus adulthood) (Wenzel et  al.). Since then, 
Enfumosa Network [2] identified that patients with 
chronic severe asthma were more likely to be female, 
overweighted, less atopic and pointed out exposure to 
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aspirin for some subjects. The SARP consortium in USA 
identified three clusters in adult patients with severe 
asthma [3]: early onset allergic asthma, late onset non-
atopic asthma, severe asthma with fixed airflow. Then, 
the TENOR project found some similarities with the 
SARP clusters, for four of five clusters [4]. Interestingly, 
associations were made between asthma phenotypes 
and asthma-related health outcomes i.e. quality of life. In 
these phenotypes, atopic status but also non-white race 
were distinguishing variables for both children and ado-
lescents. In Europe, some severe asthma registries have 
been developed in UK [5], in Belgium [6], and in Italy 
[7]. According to the Belgium Registry, the majority of 
severe asthmatics were female and atopic, revealing that 
description of patients depends on existence of network 
and inclusion of patients at baseline [6]. The same snap-
shot was described in the Italian Registry [7]. By contrast, 
in the UK registry [5], five clusters were described: atopic 
early onset asthma, obese with late onset asthma, least 
severe asthma, eosinophilic late onset-asthma and fixed 
airflow obstruction. They also find a poor stability in this 
longitudinal analysis.
In France, data regarding severe asthma management 
are scarce, a recent study estimated that prevalence of 
severe asthma was about 3.8% [8], in line in estimated 
prevalence of severe asthma 3.6% in previous surveys 
[9]. In addition, two thirds of patients with severe asthma 
are managed in non-specialized environment [10]. 9.8% 
(range 3.5–17.5%) of patients with severe asthma in real 
life was found to be eligible for enrolment in the phase III 
trials [11]. FASE-CPHG (France Asthme Sévère—Collège 
des Pneumologues des Hôpitaux Généraux) was built in 
2016 as descriptive, multicentric and observational cross-
sectional study in patients with severe asthma conducted 
in general hospitals in France.
The aim of our study was to describe the clinical phe-
notypes of severe asthma adults, in a real-life study in 
France using cluster analysis.
Methods
Study population
CPHG is a collaborative group of pulmonologists work-
ing in non-academic hospitals. One hundred and ten 
centers accepted to participate to the study. The method-
ology and descriptive analysis have been published else-
where [12].
This study was approved by the local ethics committee 
(Comité Consultatif sur le Traitement de l’Information 
en matière de Recherche dans le domaine de la Santé 
(CCTIRS)) and was conducted according to the French 
law and guidelines on epidemiological and descriptive 
studies.
Pulmonologists from an extensive list of practitioners 
were contacted to confirm their willingness to partici-
pate in the FASE-CPHG observational study. During the 
inclusion period, selected pulmonologists were required 
to recruit all patients who meet the eligibility criteria to 
ensure exhaustivity. Moreover, and for the same reason, 
patients who refused to participate in the study were 
logged in a non-inclusion register.
To join the study, patients must have fulfilled all of the 
following criteria: aged over 18  years old with a severe 
asthma diagnosis according to the physician and based 
on Global INitiative for Asthma (GINA) [1]. All sub-
jects were informed during a regular visit by the physi-
cian before being enrolled. Patients diagnosed with solid 
cancer or malignant hemopathy where excluded and also 
those who refuse to participate in the study.
According to GINA criteria, severe asthma is defined 
as asthma that requires Step 4 or 5 treatment to prevent 
it from becoming ‘uncontrolled’, or asthma that remains 
‘uncontrolled’ despite this treatment. Uncontrolled step 
3 patients were also considered as severe asthmatics as 
the adjustment strategy in case of uncontrolled asthma 
per 3 months would be to step up treatment up to step 4. 
After validation by the physicians, patients only treated 
with short acting beta agonist were excluded from analy-
ses as it is considered as non-severe asthma according to 
GINA criteria.
Patient data collection
Physician completed a secure electronic Case Report 
Form (eCRF), during a regular visit on patient charac-
teristics (sociodemographic data, potential asthma trig-
gers, medical history, comorbidities, clinical parameters, 
spirometry, blood eosinophils) and asthma ongoing treat-
ment for all patients seen during the study period.
In addition, patients were required to fill in auto-ques-
tionnaires comprising items on asthma control (Asthma 
Control Test (ACT)), anxiety and depression (Hospital 
Anxiety and Depression Scale (HADS)).
Data management
Data were entered into databases managed by Kappa 
Santé, Paris, France. Duplicates were identified with indi-
rectly nominative data (initial, age and sex) and reviewed 
with participant pulmonologists. In addition of online 
control present on eCRF, data were reviewed before 
database was frozen freeze for other errors, omissions or 
inconsistencies by a scientific committee.
Patients enrolled by participant physician with no com-
pleted CRF were removed from the analysis.
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Statistical analysis
All statistical analyses were performed using SAS (ver-
sion 9.4, SAS Institute Inc., Carey, North Carolina, USA). 
P value < 0·05 was regarded as statistically significant.
Qualitative variables are summarized as raw and fre-
quencies; number of missing data is specified. Quanti-
tative data is expressed as numbers of analyzed values, 
mean with standard deviation.
Asthma control was evaluated using the ACT, a 5-item 
questionnaire (activity limitation, shortness of breath, 
night symptoms, use of rescue medication and self-per-
ception of asthma control). Each parameter was scored 
from 1 (poorly control) to 5 (well controlled). The HADS 
was used to evaluate anxiety and depression symptoms 
in patients. The HADS is based on 14-items and pro-
duces two scales: one for anxiety (HADS-A) and one for 
depression (HADS-D). A score ≥ 11 on either scale indi-
cate a definitive case whereas score < 7 generally indicates 
an absence of the trouble.
Cluster analysis
Eighteen variables (gender, BMI, age, age of asthma 
onset, severe asthma attacks with ICU, FEV1, clinical 
atopy, exacerbations, allergenic sensitization, aspirin 
intolerance, nasal polyposis, chronic rhinitis, apnea syn-
drome, reflux, hypertension, smoking status, and eosino-
phils count) have been included in the analysis. Missing 
data were most frequent for eosinophils count, and two 
methods have been performed with and without imputa-
tion data.
A hierarchical bottom-up classification method using 
Ward’s method is then carried out, using an agglomera-
tion (ascending) approach and a ward distance (Fig.  1). 
With each generation of clusters, samples are merged 
into larger clusters to minimize the sum of intra-clus-
ter squares, while maximizing the sum of inter-cluster 
squares. In order to compare the differences between the 
resulting clusters, ANOVA, the Kruskal–Wallis test and 
The Pearson Khi Two test are used respectively for con-
tinuous parametric variables, continuous non-parametric 
variables and categorical variables (classes). The den-
drograms were produced and were examined to help to 
determine the number of clusters as shown on Fig. 1.
Fig. 1 Hierarchical bottom‑up classification using Ward Method
Page 4 of 10Raherison‑Semjen et al. Respir Res          (2021) 22:136 
Results
One thousand and four hundred twenty four patients 
from 107 centers were included in this analysis. A five 
cluster model best described the dataset. Their character-
istics are as shown in Table 1.
Cluster 1 comprised 47% of the cohort, had early onset 
allergic asthma (52% with asthma before 12 years), clus-
ter 2 (n = 153, 10.5%,) comprised obese asthma (63.4% 
with BMI > 30 kg/m2), more often men, cluster 3 (n = 299, 
20.4%) had late-onset asthma with 60.2% having asthma 
after 40  years old, cluster 4 (n = 143, 9.8%) comprised 
eosinophilic asthma (51.7% had more than 500 eosino-
phils/mm3), and cluster 5 (n = 139, 9.5%) had aspirin sen-
sitivity asthma (with 63% had severe asthma attacks).
Regarding allergenic sensitization, 79.3% of patients 
in cluster 1 had skin prick test positivity. Nasal polypo-
sis was more reported in patients of cluster 4, in patients 
having eosinophilic profile, and in cluster 5 in patients 
having also aspirin sensitivity. Chronic rhinitis and rhi-
nosinusitis were more frequent in cluster 4 and 5. By 
contrast, obstructive apnea syndrome was exclusively 
reported in cluster 2, with others comorbidities as reflux, 
hypertension and smoking history (Table 2).
Food allergy and drug allergy was more associated in 
cluster 5, most of the comorbidities were associated with 
cluster 2 i.e. diabetes, ischemic cardiopathy, and depres-
sion (Table 3).
Osteoporosis was not associated with specific cluster. 
The number of comorbidities was particularly high in 
cluster 2. The frequency of frequent exacerbation profile 
was present in each cluster, however the number of exac-
erbations requiring an increase of treatment either oral 
corticosteroids or inhaled treatment was higher in eosin-
ophilic cluster (named cluster 4) and aspirin sensitivity 
(cluster 5). Patients from cluster 2 had higher emergency 
visits compared to others patients. Absenteeism related 
to asthma was more frequent in patients from cluster 1 
and cluster 5.
House dust mite sensitization was more related in 
cluster 1 having early onset asthma, and was very low in 
late-onset asthma (cluster 3). Sensitization to molds and 
cockroaches were also lower in late-onset asthma clus-
ter, non-atopic. The distribution of blood eosinophils is 
presented by cluster (Table  3). Despite a large propor-
tion of patients having more than 500 eosinophil counts 
in cluster 4, eosinophilic distribution was heterogene-
ous across the different clusters. Among 1462 patients, 
19% had missing data regarding blood eosinophils or IgE 
level, 55.6% (n = 814) (Additional file  1: Table  S1) had 
blood eosinophils count and IgE level, 19% had blood 
eosinophils count but no IgE, and 6.4% had IgE levels 
but no blood eosinophils count available. Finally, 12.7% 
of the patients had low TH2 profile, 13% eosinophilic 
non-allergic profile, 28.5% had allergic non-eosinophilic 





















Gender Male 229 (33.2%) 81 (52.9%) 112 (37.5%) 69 (48.3%) 40 (28.8%) 531 (37.3%)  < 0.0001
Female 461 (66.8%) 72 (47.1%) 187 (62.5%) 74 (51.7%) 99 (71.2%) 893 (62.7%)
BMI  < 21 kg/m2 23 (3.3%) 1 (0.7%) 10 (3.3%) 4 (2.8%) 6 (4.3%) 44 (3.1%)  < 0.0001
21–25 kg/m2 278 (40.3%) 12 (7.8%) 101 (33.8%) 59 (41.3%) 44 (31.7%) 494 (34.7%)
25–29 kg/m2 198 (28.7%) 43 (28.1%) 119 (39.8%) 48 (33.6%) 57 (41%) 465 (32.7%)














Age at baseline [18–40] 216 (31.3%) 4 (2.6%) 18 (6%) 18 (12.6%) 20 (14.4%) 276 (19.4%)  < 0.0001
[40–60] 307 (44.5%) 62 (40.5%) 87 (29.1%) 59 (41.3%) 56 (40.3%) 571 (40.1%)














Age at onset of 
asthma
 < 12 years 359 (52%) 33 (21.6%) 28 (9.4%) 32 (22.4%) 35 (25.2%) 487  (34.2%)  < 0.0001
[12–40] 256 (37.1%) 52 (34%) 91 (30.4%) 67 (46.9%) 67 (48.2%) 533 (37.4%)














Severe asthma attacks Ever 362 (52.5%) 93 (60.8%) 135 (45.2%) 60 (42%) 88 (63.3%) 738 (51.8%)  < 0.001
FEV1, % pred Means (± sd) 73.2 (± 19.3) 68 (± 21) 68.2 
(± 22.2)
76.7 (± 20.2) 75.7 (± 22)  < 0.0001
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profile and 26.9% had eosinophilic and allergic profile. 
Lung function results showed that the high proportion 
of patients having FEV1 < 60% was in cluster 2 (obese 
patients with comorbidities) and in cluster 3 late-onset 
non-atopic asthma Additional file 1: Table S2). Obstruc-
tive syndrome with low FEV1/FVC ratio was more 
























SPT positivity 547 (79.3%) 81 (52.9%) 33 (11%) 67 (46.9%) 83 (59.7%) 811 (70%)  < 0.0001
Aspirin sensitivity Yes 1 (0.1%) 12 (7.8%) 0 (0%) 1 (0.7%) 139 (100%) 153 (10.7%)  < 0.0001
Nasal polyposis Yes 12 (1.7%) 21 (13.7%) 5 (1.7%) 143 (100%) 77 (55.4%) 258 (18.1%)  < 0.0001
Allergic rhinitis Yes 323 (46.8%) 69 (45.1%) 96 (32.1%) 80 (55.9%) 74 (53.2%) 642 (45.21%)  < 0.0001
Rhinosinusitis Yes 137 (19.9%) 33 (21.6%) 55 (18.4%) 65 (45.5%) 62 (44.6%) 352 (24.7%)  < 0.0001
Obstructive apnea syn‑
drome
Yes 0 (0%) 153 (100%) 1 (0.3%) 1 (0.7%) 1 (0.7%) 156 (11%)  < 0.0001
Reflux history Yes 231 (33.5%) 75 (49%) 129 
(43.1%)
50 (35%) 70 (50.4%) 555 (39%)  < 0.0001
Hypertension Yes 119 (17.2%) 83 (54.2%) 102 
(34.1%)
20 (14%) 37 (26.6%) 361 (25.4%)  < 0.0001
Smoking history Active smoker 108 (15.7%) 8 (5.2%) 32 (10.7%) 7 (4.9%) 11 (7.9%) 166 (11.7%)  < 0.0001
Ex‑smoker 176 (25.5%) 61 (39.9%) 85 (28.4%) 49 (34.3%) 40 (28.8%) 411 (28.9%)
No‑smoker 406 (58.8%) 84 (54.9%) 182 
(60.9%)
87 (60.8%) 88 (63.3%) 847 (59.5%)
Blood eosinophil count  < 300 331 (48%) 66 (43.1%) 150 
(50.2%)
36 (25.2%) 63 (45.3%) 646 (45.4%)  < 0.0001
[300–500] 176 (25.5%) 46 (30.1%) 63 (21.1%) 33 (23.1%) 28 (20.1%) 346 (24.3%)
 ≥ 500 183 (26.5%) 41 (26.8%) 86 (28.8%) 74 (51.7%) 48 (34.5%) 432 (30.3%)























Fernand widal syndrome Yes 3 (0.4%) 6 (3.9%) 0 (0%) 16 (11.2%) 72 (51.8%) 97 (6.8%)  < 0.0001
Food allergy Yes 78 (11.3%) 17 (11.1%) 12 (4%) 14 (9.8%) 25 (18%) 146 (10.3%)  < 0.01
Drug allergy Yes 69 (10%) 28 (18.3%) 35 (11.7%) 15 (10.5%) 54 (38.8%) 201 (14.1%)  < 0.0001
Atopic dermatitis Yes 130 (18.8%) 18 (11.8%) 19 (6.4%) 19 (13.3%) 33 (23.7%) 219 (15.4%)  < 0.0001
Allergic broncho‑pulmonary 
aspergillosis
Yes 22 (3.2%) 2 (1.3%) 6 (2%) 1 (0.7%) 5 (3.6%) 36 (2.5%) 0.28
Vascularitis Yes 6 (0.9%) 1 (0.7%) 5 (1.7%) 3 (2.1%) 0 (0%) 15 (1.1%) 0.33
Diabetus Yes 46 (6.7%) 35 (23%) 42 (14.1%) 7 (4.9%) 11 (8%) 141 (10%)  < 0.0001
Ischemic cardiopathy Yes 22 (3.2%) 16 (10.5%) 17 (5.7%) 9 (6.3%) 6 (4.3%) 70 (4.9%)  < 0.001
Osteoporosis Yes 58 (8.4%) 17 (11.1%) 36 (12.1%) 23 (16.1%) 19 (13.7%) 153 (10.8%) 0.16
Anxiety (HAD‑A) Means (Sd) 7.6 (± 4.5) 7.5 (± 4.5) 7.3 (± 4.2) 7 (± 4.4) 7.1 (± 4.7) 7.4 (± 4.4) 0.52
Depression (HAD‑D) Means (Sd) 4.6 (± 3.6) 5.6 (± 4.1) 5.4 (± 3.9) 5.3 (± 4.2) 5.3 (± 3.7) 5 (± 3.8)  < 0.01
Number of comorbidities 
(outside ENT)
0 247 (35.8%) 0 (0%) 57 (19.1%) 47 (32.9%) 27 (19.4%) 378 (26.6%)
1 212 (30.8%) 24 (15.7%) 92 (30.9%) 52 (36.4%) 42 (30.2%) 422 (29.7%)
2 120 (17.4%) 33 (21.6%) 75 (25.2%) 23 (16.1%) 33 (23.7%) 284 (20%)
3 or more 110 (16%) 96 (62.7%) 74 (24.8%) 21 (14.7%) 37 (26.6%) 338 (23.8%)
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important in cluster 2 and cluster 5 (aspirin sensitiv-
ity cluster). Obstruction of small airways was common 
whatever the cluster group (Table 4).
Regarding therapeutic management (Additional file  1: 
Table S3), a proportion of patients was still not-compli-
ant to treatment according to Moriski scale (< 3). Anti-
leukotrienes were more prescribed than anti-cholinergic 
treatment. The prescription of regular oral corticoster-
oids was higher in cluster 2 (obese patient with comor-
bidities). Omalizumab was prescribed in one third of the 
patients. A high proportion of patients had no physical 
activity, the greatest proportion was belong to cluster 2 
(obese patients with comorbidities) (Table 5).
Discussion
In this large real-life study including difficult-to severe 
asthmatic patients followed by pulmonologist in non-
academic general hospitals, we described five phenotypes 
of patients using cluster analysis. The five cluster analy-
sis were described cluster 1 (47%) the most atopic with 
early-onset disease, cluster 2 (10.5%) obese asthmatic 
with high prevalence of comorbidities (more than 3) 
including obstructive apnea syndrome, cluster 3 (20.4%) 
the late-onset asthma without atopy, cluster 4 (9.8%) 
eosinophilic asthma with nasal polyposis, and cluster 5 
with aspirin sensitivity asthma.
Regarding the general characteristics of the popu-
lation, our population is in line with what had been 
recently published by the International Severe Asthma 
Registry [13] and the ERS severe asthma registries [14]. 
Patients were predominantly female, with overweight 
or obesity, and non-smoker. Most of patients having 
uncontrolled asthma on GINA step 5 or on GINA step 
4. 65.8% developed also asthma after 12 years old in our 
population compared to 77.5% in the ISAR registry. The 
mean number of exacerbation was higher in our popula-
tion (2.5) vs (1.7) in the ISAR registry, with a significant 
heterogeneity across countries. Lung function before 
and after bronchodilator was quite similar to the ISAR 
global value, with little improvement after bronchodila-
tor. Unfortunately we couldn’t compare the FeNO meas-
urements, as in our study most of practitioners could not 
access to this evaluation tool. In our population, 47.6% of 
patients had IgE lower than 200 UI/l compared to half of 
the ISAR registry, who had lower IgE concentration. In 
the same trend, 50% of our patients had a blood eosin-
ophils count > 0.3 *  109 cells/L. Allergic rhinitis was the 
predominant comorbidity, followed by reflux and hyper-
tension. The prevalence of nasal polyps was higher in our 
population (18%) vs 7.3% in the ISAR registry. We could 
not compare the prevalence of OSA or cardiovascular 
comorbidity, or osteoporosis, not reported in the ISAR 
publication. 16.9% of the patient received regular oral 
corticosteroids compared to 30.1% of the ISAR cohort. In 
the ISAR registry, 25.4% of the patients were on biologics, 
very similar to what we found in our population; however 






















More than 2 exacerbations Yes 442 (64.1%) 101 (66%) 185 (61.9%) 97 (67.8%) 100 (71.9%) 925(65%) 0.26
Number of exacerbations 
with increased of OCS 
or ICS
Means (± sd) 2.6 (± 3.2) 2.6 (± 3) 2.2 (± 2.6) 2.9 (± 3.6) 2.9 (± 3.1) 2.5 (± 3.1) 0.03
Median 2 2 1 2 2 2
Min–Max 0–20 0–16 0–15 0–20 0–20 0–20
Number of hospitalizations 
during the 12 past months
Means (± sd) 0.4 (± 1.2) 1 (± 1.8) 0.6 (± 1.3) 0.4 (± 1.5) 0.4 (± 1) 0.5 (± 1.3)  < 0.0001
Min–Max 0–12 0–12 0–12 0–15 0–6 0–15
Number of emergency visits 
during the 12 past months
Means (± sd) 0.6 (± 1.7) 0.9 (± 2.1) 0.6 (± 1.5) 0.5 (± 1.8) 0.5 (± 1.1) 0.6 (± 1.7) 0.04
Min–Max 0–20 0–15 0–12 0–17 0–6 0–20
Number of medical visits 
during the 12 past months
Means (± sd) 2.6 (± 3.1) 2.8 (± 3.5) 2.2 (± 2.5) 3.1 (± 4) 2.9 (± 3.2) 2.6 (± 3.1) 0.19
Median 2 2 2 2 2 2
Min–Max 0–20 0–20 0–12 0–20 0–20 0–20
Absenteism related to 
asthma during the 12 past 
months
Yes 113 (16.4%) 15 (9.8%) 24 (8%) 16 (11.2%) 21 (15.1%) 189 (13.3%))  < 0.0001
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anti-IL5 was not available in France at the beginning of 
our study, explaining that anti-IgE was the most predom-
inant prescription. Only 5% of patients had azithromycin 
prescription, lower than 9.2% of the patients from the 
ISAR registry.
Our cluster analysis revealed 5 clusters, 4 of them have 
been mostly described in previous studies: the classic 
early onset severe allergic asthma, the obese asthma with 
high impairment, the late-onset non-atopic cluster and the 
eosinophilic phenotype. Enfumosa Network [2] identified 
previously that patients with chronic severe asthma were 
more female, more in overweight, less atopic and pointed 
out exposure to aspirin for some subjects. The SARP con-
sortium in the US identified three clusters in adult patients 
with severe asthma [3] using unsupervised cluster analyses: 
early onset allergic asthma, late onset non-atopic asthma, 
severe asthma with chronic airflow obstruction.Then, the 
TENOR project found some similarities with the SARP 
clusters, for four of five clusters [4] using hierarchical clus-
tering. As us, they also identified a phenotype of adult-onset 
asthma with aspirin sensitivity, which is underreported in 
the literature. In the UK registry, five clusters [5] have been 
identified using a two way cluster/mixture analysis with the 
Bayesian information criterion: atopic early onset asthma, 
obese with late onset asthma, least severe asthma, eosino-
philic late onset-asthma and fixed airflow obstruction. 
Amelink et  al. [15] identified two clusters using K-means 
nonhierarchical cluster analysis: one with severe eosino-
philic inflammation and another with frequent symptoms, 
high healthcare utilization and low sputum eosinophils. 
Newby et al. (2014) [16] identified also four clusters: early 
onset atopic, late-onset in obese patients, eosinophilic 
asthma, non-atopic with normal lung function and one 
group with reversible obstruction. The obese asthma phe-
notype has been already described, however in our analysis, 
we pointed out that this group was at higher risk of comor-
bidities, cardiovascular diseases, OSA, ex-smoker status; 
in addition, two third of them had more than 3 comorbidi-
ties outside ENT comorbidities. In addition, 30% of them 
had prescription of oral corticosteroids, so we cannot for-
mally exclude that this group of patients had comorbidi-
ties induced by oral steroids [17]. They also had the worse 
lung function regarding FEV1 or FEV1/FVC ratio before 
and after bronchodilatator, and the lowest physical activity 
compared to the other clusters. One major difference from 
the other studies was that in our obese cluster, atopy was 
present in half of the group. The UK registry [16] identi-
fied five clusters: atopic early onset asthma, obese with late 
onset asthma, least severe asthma, eosinophilic late onset-
asthma and fixed airflow obstruction. In the eosinophilic 
phenotype, 20% had nasal polyps whereas in our cluster 
analysis 100% of the patients had nasal polyps. However, 
the mean of blood eosinophilic count was very similar. We 
described also the late-onset non-atopic asthma, which was 
described previously in Tenor cohort, the main difference 
with the Sharp study was obesity [4].
Our study had some limitations. The recruitment of 
severe asthmatic patients was made by pulmonologist 
from non-academic hospitals, not from university hospi-
tals or primary care, so we cannot generalize the findings 
of our study to the whole population of severe asthmatics 
in France. This explained also why FeNO was not available 
for the majority of the centers. It is noteworthy that FeNO is 
not a recognized tool for monitoring asthma by the national 
insurance French authority at the time this paper was writ-
ten. The SHARP ERS consortium found that severe asth-
matic patients in Europe is heterogeneous, and differs in 
both clinical characteristics and treatment, most of regis-
tries enrolled patients being treated in a tertiary care center, 
however small centers included patients with severe asthma 
from primary care and second care hospitals [14].
Our statistical analysis had performed imputation algo-
rithms to allow missing values, particularly for eosinophils 
counts. We made sensitivity analysis with and without impu-
tation, the results did not change. We presented an unbi-
ased statistical cluster analysis technique, which selects the 
number of the cluster based on the data. However, we must 
admit that bias could come from the choice of the variables 
included in the cluster analysis. The confidence that we have 
in our analysis, is that some of our clusters had been already 
shown in others registries, in UK or in USA. Another limit 
of our study is the cross-sectional design of the analysis, so 
we would not able to ensure stability of the clusters. In addi-
tion, there is a heterogeneity in cluster analysis (supervised 
vs unbiased) in the different studies that made difficult the 
comparison. None analysis has shown a superiority to 
another. The impact of OCS on blood eosinophils count is 
difficult to analyze, patients with OCS seem to have more 
eosinophils count than patients without OCS, suggesting 
that patients with OCS could have TH2 profile, compared to 
the others Additional file 1: Fgure S4, S5, Table S6.
Conclusion
Despite these limitations, we were able to describe five 
clusters in a very large population of difficult-to severe 
asthmatic managed by pulmonologist in non-academic 
hospitals in France; early onset atopic cluster, obese-late 
onset asthma with high comorbidities, late-onset non-
atopic asthma, eosinophilic asthma with nasal polyps and 
aspirin sensitivity. Understanding heterogeneity of severe 
asthma in real life remains an important challenge to 
input personalized medicine, many of these patients are 
still excluding for the moment from randomized clinical 
trials.
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